Calporta Therapeutics Overview

  • Founded
  • 2015
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $576M
Latest Deal Amount

Calporta Therapeutics General Information


Developer of medicinal product designed to offer treatment of niemann-pck C disease. The company's products include selective small molecule agonists of transient receptor potential cation channel for the treatment of lysosomal storage diseases caused by mutations, enabling patients to get advanced treatment for their diseases and recover faster.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 11099 North Torrey Pines Road
  • Suite 290
  • San Diego, CA 92037
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Calporta Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 13-Nov-2019 $576M 0000 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 22-Jun-2015 0000 0000 000.00 Completed Startup
To view Calporta Therapeutics’s complete valuation and funding history, request access »

Calporta Therapeutics Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 000
To view Calporta Therapeutics’s complete cap table history, request access »

Calporta Therapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Avalon Ventures Venture Capital Minority 000 0000 000000 0
GlaxoSmithKline Corporation Minority 000 0000 000000 0
To view Calporta Therapeutics’s complete investors history, request access »